corporate presentation - jefferies · 2015-06-11 · therapeutics focused on the inhibition of...
TRANSCRIPT
Corporate PresentationJune 2015
This document contains forward-looking statements for the Company and its subsidiaries. These
forward looking statements, by their nature, necessarily involve risks and uncertainties that could
cause actual results to differ materially from those contemplated by the forward-looking statements.
The Company considers the assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared, but cautions the reader that these assumptions regarding
future events, many of which are beyond the control of the Company and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially
from current expectations are discussed in the Company’s Annual Report and in the Company’s
Annual Information Form for the year ended December 31, 2014. The Company disclaims any
intention or obligation to update or revise any forward-looking statements whether as a result of new
information or future events, except as required by law.
2
Forward Looking Statements
2
• Better a Gud Knight than a bad one
• We never rest at Knight
• May you always have a Gud-Knight
• A Gud-Knight is Gud medicine
• Knighting wrong with making money
• Gud for Knight
• Fun things happen at Knight
• Gud Knight sleep tight
• Gud time had by all
• Gudluck Jonathan
3
A Knight is Born
A Knight’s History and Overview
1 Gross proceeds from financings + Proceeds of Priority Review Voucher Sale converted to CADat 1:1.13 USD to CAD on November 19th, the day of the sale
• Founded by co-founder & CEO of Paladin Labs Inc.
– 19 years of consecutive record revenues
– Share price increased from $1.50 to $142 per share
– Market capitalization increased from $6 million to $3.2 billion
• Knight’s first day was on February 28th, 2014
– The day Paladin’s sale to Endo closed
– Knight initially owned by Paladin’s shareholders as consideration for Paladin sale
• Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets
• Well poised for executing our growth strategy with $495 million of cash1 and a leadership team that delivered 19 years of consecutive record revenues
4
A Knight’s Mission
To understand and serve the needs of Health Care professionals in specialty therapeutic areas through the development, licensing and commercialization of innovative products
Opportunology is our core specialty
55
Growth Strategies
1. License of innovative pharmaceuticals
2. Acquire mature or “under-promoted” products from Big Pharma
3. Develop near-term, low risk/low expense products for the Canadian and global markets
4. Lend, on a fully secured basis, to life science companies in need, for interest and/or product rights
6
Source of New Products
• Multinational pharmaceutical companies having non-promoted products
• Emerging specialty pharmaceutical companies with no presence in Canada or other smaller markets
• Biotech companies with products in late-stage trials who– Carve non-strategic markets, like Canada, off a global deal in order to
secure value, or
– Need cash and are willing to part with a non-strategic market
77
Product Selection Criteria
8
1 To be established based on initial product opportunities
Stage of Development
Product must be in Phase II, Phase III or approved in a foreign market
Leverage Existing Marketing Capabilities1
Product must be able to be sold through scalable distribution channels
Risk of FailureAgreement must be structured such that failure of the product will not cripple the company
Financial Return Risk must be commensurate with reward
Long-Term Licensing Strategy
• Knight to deploy up to CAD$130M in time-proven life sciences funds in order to:1. Generate LP returns and, more strategically,
2. Obtain preferential access to innovative pharmaceutical products from around the world for the Canadian market
• Investment designed to provide financial incentives to secure Canadian and international product rights, and source loan opportunities
9
Life Science Fund Strategy Execution
• Knight will invest across a variety of complementary funds to get the broadest access possible to Canadian and select international product rights– Early stage to late stage (Sectoral)
– Focus: Global, European (Forbion) and North American (Domain, Sanderling)
– Direct and fund of funds investments (Teralys, HarbourVest)
• The expectation is that Knight will have a pipeline of innovative products 5 to 10 years from now larger than Merck and Pfizer combined, albeit just for Canada and select international markets, leveraging tens of billions of dollars in R&D
10
Long-Term Licensing Strategy
11
~150Companies
~$1B Funds
~100 FailedVentures
~50 Successful Companies
Knight invests $130M into..
Funds invest ~$1B into..
Other investors contribute ~$5B into..
Subsequent Rounds/IPO contribute ~$5B into..
~$10B+ in R&D benefiting Knight albeit just for Canada and select international markets
Leads to.. Products for Knight
Illustrative
Long-Term Strategy Investments
12
Fund AmountHealthCare
AUMDevelopment Stage Geography
Sectoral US$13M US$3.6B Late stage to small cap Global
Forbion €19.5M EUR€400M All clinical stages Europe
Teralys C$30M CAD$450M VCAP Fund of Funds Canada
Domain US$25M US$2.4B Early stage North America
Sanderling US$10M US$900M Early stage North America
HarbourVest C$10M US$2.3B VCAP Fund of Funds Canada
TOTAL ~C$120M All stages Worldwide
TOTAL C$10M C$∞M All stages Worldwide
Remaining
Notable past investments by Knight’s partner funds
13
Source: Investment Fund company websites
Knight’s Assets
14
Impavido®(miltefosine)
• Partnership with Paladin globally excluding U.S.• U.S. FDA approval March 19, 2014
PHOTOFRIN®(porfimer sodium)
• Exclusive Canadian product rights• Health Canada approval
ATryn® (recombinant antithrombin)
• Exclusive Canadian product rights• Expected launch in 2016
NeurAxon family of products
• Safe and effective group of nitric oxide synthase inhibitors
FOCUSfactor®• Exclusive Canadian, Israeli, South African, Russian product rights• Health Canada approval• A clinically tested brain health supplement
Long Term Licensing Strategy
• Sectoral, Forbion, Teralys, Domain, Sanderling, HarbourVest
Secured Loan Strategy • Origin, Apicore, CRH, Synergy Strips, Pediapharm
Cash • $452 million1
1 Includes cash, cash equivalents and marketable securities (As at March 31, 2015)
Global United States
• Indicated for the treatment of cutaneous and visceral leishmaniasis
• Agreement between Paladin andKnight Therapeutics (Barbados) Inc.
• Approved for sale in 15 countries • Generic threat
• Indicated for the treatment of cutaneous, visceral and mucosal leishmaniasis
• Post marketing requirements underway• ~$1M per year early on and tapering
off over time
• Commercialization plan in development• Likely ~6 months away
Impavido Revenue Stream
15
Expected annual revenue of $200-400k Expected annual revenue of $200k+
PHOTOFRIN®
• PHOTOFRIN (porfimer sodium) is a two-stage process belonging to a group of cancer-fighting medications known as antineoplastics
– It kills cancer cells by localizing the medicine in the tumor when activated by laser light
• Exclusive Canadian rights for sales and distribution of PHOTOFRIN
– Collaboration agreement with Concordia Health Corp. (TSX:CXR) who obtained worldwide rights through its acquisition of Pinnacle for total consideration $58M• Upfront payments include $32.7M million cash consideration and $5M of CHI’s common shares
– Already approved in Canada, US, EU5 and Japan• Concordia will market PHOTOFRIN in the U.S.
• Indicated for the treatment of esophageal cancer, endobronchial cancer, high-grade dysplasia in Barret’s esophagus and papillary bladder cancer
– Global clinical trial to evaluate PHOTOFRIN in cholangiocarcinoma commencing with Canadian sites• Potential to significantly boost sales
– 10 year collaboration agreement with renewal options
16
ATryn®
• ATryn (recombinant antithrombin) is administered in a hospital setting to patients with hereditary antithrombin deficiency to avoid peri-operative and peri-partum thromboembolic events
• Exclusive license to sell ATryn in Canada (expected launch in 2016)
– 20 year agreement with rEVO Biologics
– Already approved in US and Europe for Hereditary Antithrombin Deficiency
– Seeking an initial indication for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients
– Potential upside if an additional indication is approved for the treatment of pre-eclampsia
17
NeurAxon Acquisition
18
• NeurAxon is a leader in discovering and developing next generation pain
therapeutics focused on the inhibition of neuronal nitric oxide synthase
(nNOS), an enzyme involved in modulating pain and central nervous
system neuronal sensitization
• NeurAxon holds multiple innovative products in various stages of
development that have a high probability of finding a profitable niche
• NeurAxon has total tax attributes of $74M that are expected to provide
Knight with deferred tax assets of $20.5M
• Deal: Knight paid $1.75 million and will provide additional capital to
further develop the technology
CRH: Better Lucky Than Smart!
19
Dec. 2, 2014: CRH announces acquisition supported by fully secured loan
from Knight of US$30M at 10% interest. As consideration, Knight issued 3
million CRH shares which had been trading at ~CAD$1 per share.
Q1 2015: Knight sells its CRH shares for proceeds of ~CAD$9.9M.
Mar. 25, 2015: CRH raises CAD$27.4M of equity at CAD$3.40 per share
and repays US$7.9M of secured loan principal plus interest to Knight.
GUD: 36+% IRR anticipated from CRH loan
CRH: Stock price greater than 3x prior to loanFigures as of March 25, 2015
CRH Medical
• CRH (TSX:CRH) is a North American medical company focused on providing physicians with
innovative products and services for the treatment of gastrointestinal diseases
• CRH acquired a reliably profitable Southeast US-based anesthesia services provider for an
upfront fee of US$58.6M (3.6x EBITDA) and an earn-out of US$14.6M (0.9x EBITDA)
• The acquisition was funded via a senior secured loan from Knight, a sub secured loan from
Crown Capital, an unsecured loan from Bloom Burton, an equity financing, and CRH cash
• Deal: USD $30M secured loan that bears interest at 10% plus additional consideration and
matures in December 2016, or 2017 should CRH meet profitability milestones
• In consideration, Knight received 3,000,000 shares in CRH Medical
Apicore
• Apicore is a leading process R&D and API manufacturing service provider serving the
worldwide pharmaceutical industry from its plants in the United States and India
• A majority interest in Apicore was purchased for the aggregate amount of USD$22.5M by
Signet Healthcare Partners, Medicure, Knight and Sanders Morris Harris Inc.
• Deal: USD $6.5M secured loan that bears interest at 12% and matures in June 2018
• In consideration, Knight received warrants to acquire ~8% of the new holding entities
• Medicure has a 3-year option on Knight’s warrants for a pre-determined cash amount
Fully Secured Lending (1 of 2)
20
SynergyStrips
• Synergy Strips (OTCQB:SNYR) is a US company focused on the health and wellness sector
• Synergy acquired FOCUSfactor, America’s leading brain health supplement
• Clinical test shows improvements in focus, concentration and memory
• Deal: USD $6M secured loan that bears interest at 15%1 and matures in June 2017, 2018, or 2019 at Synergy’s
option contingent on meeting certain revenue and profitability milestones
• Knight received 4,595,187 shares of Synergy representing ~6.5% fully diluted capital
• Knight also received a 10 year warrant for 3,584,759 shares at $0.34 per share
• Knight received the exclusive sales rights to FOCUSfactor and all of Synergy’s brands for Canada, Israel,
South Africa and Russia in exchange for COGS plus a supply profit
Origin Biomed Inc.
• Founded in 2001, Origin is a private Canadian consumer health products company with operations throughout
the US and Canada
• Origin’s lead product, Neuragen, is the first all-natural, non-prescription treatment for the rapid relief of nerve
related pain
• Deal: $850,000 secured loan
Pediapharm Inc.
• Pediapharm Inc. (TSX-V:PDP) is a Canadian pediatric pharmaceutical company
• Deal: $1.25M secured convertible debentures that bear interest at 12% per annum and mature in March 2019
• Knight was issued 757,500 share purchase warrants to acquire 757,500 common shares of Pediapharm
at an exercise price of $0.33 per common share
Fully Secured Lending (2 of 2)
21
1Will drop to 13% if Synergy meets equity-fundraising milestones
Strong Balance Sheet to Fund Growth
Share Price1
Shares Outstanding2
Cash, Cash equivalents and Marketable Securities2
Revenue (2014)
Loss before depreciation, amortization, interest and tax (2014)
Net Income (2014)
$7.00
~93M
~$452M
$365K
($4,947K)
1 As at May 25, 20152 As at March 31, 2015
22
$125.9M
Management Team
Jonathan Ross Goodman B.A., LL.B., M.B.A.
President & CEO
• Co-Founder, President & CEO Paladin Labs Inc.
Jeffrey Kadanoff, B. Eng., M.B.A.
Chief Financial Officer
• VP Strategic Planning and Development Reitmans (Canada) Ltd.
• Principal Bain & Company
Amal Khouri, B.Sc., M.B.A.
VP Business Development
• Novartis Global Business Development and Licensing
• Paladin Labs, Business Development
23
Board of Directors
James Gale• Paladin Board member from 2008 to 2014
• Managing Director, Signet Healthcare Partners
Jonathan Ross Goodman • Paladin Board member from 1995 to 2014
• Knight President & CEO
Robert Lande • Paladin Board member from 1995 to 2014
• CFO Forex Capital Markets LLC
Ed Schutter • President and CEO of Arbor Pharmaceuticals, LLC
Sylvie Tendler• Pharmaceutical Market Research Consultant
• Founder of The Tendler Group Inc.
24
0
50,000
100,000
150,000
200,000
250,000
300,000
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Paladin’s Performance Over Time
Knight’s Objectives
25
EBITDA
Revenues
Stock
140
120
100
80
60
40
20
160
180
200
SharePrice ($)
Revenue/EBITDA ($k)
Summary
• Proven ability to develop a rich pipeline of new
products in specialty therapeutic areas
• Proven ability to secure profitable licensing
agreements
• Proven track record of profitable growth
• Proven strategy
• Experienced and dynamic management team
• Financial strength to execute our strategy
26